This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heifets, L.
Right arrow Articles by Pham, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heifets, L.
Right arrow Articles by Pham, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1999, p. 25-28, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Development of Rifapentine Susceptibility Tests for Mycobacterium tuberculosis

L. Heifets,* T. Sanchez, J. Vanderkolk, and V. Pham

National Jewish Medical and Research Center and University of Colorado Health Sciences Center, Denver, Colorado

Received 15 June 1998/Returned for modification 29 September 1998/Accepted 25 October 1998

Two methods for testing the susceptibility of Mycobacterium tuberculosis to rifapentine have been developed: the agar proportion method and the radiometric BACTEC technique. A critical concentration of 0.5 µg of rifapentine per ml is proposed for both methods since it provides a reliable means of distinguishing between susceptible and resistant M. tuberculosis isolates. It is recommended that two quality control M. tuberculosis strains be used at the introduction of these tests in a clinical laboratory: one that is pansusceptible (H37Rv) and one that is resistant to rifapentine. The resistant strain can be obtained from the American Type Culture Collection, where it is deposited under the number ATCC 700457.

* Corresponding author. Mailing address: National Jewish Medical and Research Center, 1400 Jackson St., Denver, CO 80206. Phone: (303) 398-1384. Fax: (303) 398-1953. E-mail: heifetsl{at}njc.org.

Antimicrobial Agents and Chemotherapy, January 1999, p. 25-28, Vol. 43, No. 1
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kocagoz, T., Saribas, Z., Alp, A. (2005). Rapid Determination of Rifampin Resistance in Clinical Isolates of Mycobacterium tuberculosis by Real-Time PCR. J. Clin. Microbiol. 43: 6015-6019 [Abstract] [Full Text]  
  • Saribas, Z., Kocagoz, T., Alp, A., Gunalp, A. (2003). Rapid Detection of Rifampin Resistance in Mycobacterium tuberculosis Isolates by Heteroduplex Analysis and Determination of Rifamycin Cross-Resistance in Rifampin-Resistant Isolates. J. Clin. Microbiol. 41: 816-818 [Abstract] [Full Text]  
  • Rastogi, N., Goh, K. S., Berchel, M., Bryskier, A. (2000). Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother 46: 565-570 [Abstract] [Full Text]  
  • Bemer-Melchior, P., Bryskier, A., Drugeon, H. B. (2000). Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother 46: 571-576 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., McQuitty, M., Kipps, J., Lin, E. T., Zurlinden, E. (2000). Single-Dose Intrapulmonary Pharmacokinetics of Rifapentine in Normal Subjects. Antimicrob. Agents Chemother. 44: 985-990 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»